Biocon Limited (NSE:BIOCON)
India · Delayed Price · Currency is INR | Market Cap | 618.62B +57.0% |
| Revenue (ttm) | 168.27B +14.0% |
| Net Income | 6.04B -24.9% |
| EPS | 4.76 -29.1% |
| Shares Out | 1.62B |
| PE Ratio | 80.29 |
| Forward PE | 82.67 |
| Dividend | 0.50 (0.13%) |
| Ex-Dividend Date | Jul 4, 2025 |
| Volume | 5,104,865 |
| Average Volume | 2,974,205 |
| Open | 379.00 |
| Previous Close | 382.25 |
| Day's Range | 377.25 - 396.40 |
| 52-Week Range | 317.90 - 424.95 |
| Beta | 0.23 |
| RSI | 68.30 |
| Earnings Date | May 7, 2026 |
About Biocon
Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, a... [Read more]
Financial Performance
In fiscal year 2025, Biocon's revenue was 152.62 billion, an increase of 3.43% compared to the previous year's 147.56 billion. Earnings were 10.13 billion, a decrease of -0.90%.
Financial StatementsNews
Biocon Earnings Call Transcript: Q4 2026
FY 2026 saw strong biosimilars-led growth, improved margins, and successful integration of business units. The company completed its major investment phase, shifted focus to execution and de-leveraging, and expects new product launches to drive further growth and profitability in FY 2027.
Top Stocks For Trade Today, May 8: Thermax, Dabur India, Biocon, MGL, ONGC, Oil India and more
Indian stock market investors are expected to track a mix of Q4 earnings, major order wins, block deals, and developments linked to crude oil prices on May 8. Here are…
Biocon reports Rs 17,270 crore total income for FY26 with 14% growth
Biocon Limited, an innovation-led global biopharmaceuticals company, announced its consolidated financial results for the fiscal fourth quarter and the financial year ended March 31, 2026. The company...
Pharma sector stocks today, May 7: Wockhardt falls 4%, Panacea Biotec jumps 2.16%, Biocon up 1%
Pharma sector performance remained largely stable in early trading on May 7, 2026. The NIFTY PHARMA Index stood at 24,108.9, showing no change (down 0.0%). The broader S&P BSE HEALTHCARE…
Mazumdar-Shaw picks niece Claire as Biocon successor
India Business News: Kiran Mazumdar-Shaw, founder and chairperson of Biocon, has found her successor within the family. She outlined a gradual succession plan, naming her .
Who Is Claire Mazumdar? Meet Kiran Mazumdar-Shaw's Chosen Successor At Biocon
Claire Mazumdar, 37, is a biotech specialist and the founding CEO of Bicara Therapeutics, a clinical-stage oncology firm incubated by Biocon.
Who is Claire Mazumdar? Kiran Mazumdar-Shaw's Chosen Successor At Biocon
Claire Mazumdar, 37, is a biotech specialist and the founding CEO of Bicara Therapeutics, a clinical-stage oncology firm incubated by Biocon.
Kiran Mazumdar-Shaw picks niece Claire Mazumdar as successor at Biocon: Report
Claire Mazumdar, 37 years of age, currently heads Bicara Therapeutics as its founder and CEO. The firm, which was incubated by Biocon and later listed on NASDAQ, went public in 2024 and now has a mark...
Pharma sector stocks today, April 30: Biocon falls 1.01%, Torrent Pharma down 0.95%, Zydus Lifesciences drops 0.85%
Indian pharmaceutical stocks opened the last trading session of April 2026 on a broadly weak note, with the majority of pharma scrips trading in the red in early trade. The…
Biocon receives five observations from U.S. FDA after pre-license inspection
The U.S. Food and Drug Administration (FDA) has concluded a Pre-License Inspection (PLI) at Biocon's biosimilars site located at Biocon Park in Bengaluru, India. The inspection, which took place from…
Biocon reports Rs 200 crore commercial paper issuance for March quarter
Biocon Limited has issued a quarterly certificate confirming the utilisation of proceeds from its commercial paper (CP) issuance for the quarter ending 31 March 2026. The total issuance of CPs…
Gadkari promised to repair Hosur Rd by April-end: Shaw
Bengaluru: Biocon chairperson and entrepreneur Kiran Mazumdar-Shaw Thursday said Union minister for road transport and highways Nitin Gadkari had assu.
Biocon secures Health Canada approval for Bosaya and Vevzuo biosimilars
Biocon Limited has achieved a significant milestone with Health Canada granting approval for its biosimilar products, Bosaya™ and Vevzuo™. These denosumab-based biosimilars are equivalent to Prolia® a...
Biocon issues reminder for KYC updates to shareholders with physical holdings
Biocon has issued a reminder to its shareholders holding shares in physical form to update their KYC details. This action follows the SEBI Master Circular dated February 6, 2026, which…
Pharma sector stocks fall today, April 13: Biocon falls 2.35%, Cipla down 1.66%, Ajanta Pharma gains 0.77%
Pharmaceutical sector stocks traded mostly lower in early trade on Monday, April 13, 2026, with most counters under pressure. The S&P BSE Healthcare Index declined 0.88% to 42,246.47, while the…
Biocon shares jump over 3% after US FDA nod for diabetes drug Dapagliflozin tablets
Biocon shares surged more than 3% in early morning trade on April 8, after the company announced a key regulatory approval from the US health regulator, boosting investor sentiment. The…
Biocon receives U.S. FDA approval for Dapagliflozin tablets
Biocon Pharma Limited, a subsidiary of Biocon Limited, has announced the receipt of approval from the U.S. Food and Drug Administration (FDA) for its Dapagliflozin Tablets, available in 5 mg…
Biocon launches Bosaya and Aukelso biosimilars in the U.S.
Biocon Limited, a global biopharmaceutical company, has announced the commercial launch of its denosumab biosimilars, Bosaya™ and Aukelso™, in the United States. These products, which are biosimilars ...
Pharma sector stocks fall sharply today: Sun Pharma down 4.89%, Aurobindo Pharma falls 4.48%, Biocon drops 4.67%
Indian pharmaceutical stocks declined in early trade on April 2, 2026, with most listed companies showing losses on both BSE and NSE. As of approximately 9:23-9:25 AM IST, the majority…
Biocon changes name of step-down subsidiary to Biocon Biologics Ireland
Biocon Limited has announced a change in the name of its step-down subsidiary. The entity previously known as Biosimilar Collaborations Ireland Limited, a subsidiary of Biocon Biologics Limited (BBL),...
Biocon announces changes in trustees for employee welfare trust
Biocon Limited has announced changes to the trustees of its Employees Welfare Trust, effective from 1 April 2026. The modifications were made in accordance with Article 13 of the Trust…
Biocon appoints Shreehas Tambe as CEO and Managing Director effective April 2026
Biocon Limited has announced the appointment of Shreehas Tambe as its Chief Executive Officer and Managing Director, effective 1 April 2026. This decision follows approvals from the Nomination & Remun...
St Patrick’s Day celebrated in Bengaluru with focus on India-Ireland ties
Bengaluru: Kiran Mazumdar-Shaw, honorary Consul General of Ireland and chairperson of Biocon, and Kevin Kelly, Ambassador of Ireland to India, hosted .
Pharma sector stocks fall today, March 19: Biocon down 2.33%, Laurus Labs falls 2.29%, Glenmark Pharma drops 2%
Pharmaceutical stocks in India experienced a decline on March 19, 2026, during early trading hours. Market data as of approximately 9:46 AM IST (BSE) and 9:49 AM IST (NSE) showed…
Biocon receives U.S. FDA approval for Liraglutide injection
Biocon Pharma Limited, a wholly-owned subsidiary of Biocon, has secured approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Liraglutide I...